Clinical Trial

Blood Based Biomarkers for Pancreas Adenocarcinoma

Study Description

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Diagnostic Test - Blood Draw

If clinically safe, up to approximately 50ml of blood will be drawn, not to exceed the following criteria: Patients and controls weighing 50kg or more For draw amounts up to 50mL, there is no required hemoglobin threshold. For amounts exceeding 50mL, patients who meet standard blood banking criteria (e.g., hemoglobin values within normal limits and minimum weight of 50kg) may give as much as a full unit of blood (500mL) at one time or in divided fractions over a 56 day/eight week period. Patient ...read more on ClinicalTrials.org

Diagnostic Test - Tumor Tissue Collection

Tumor tissue will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

Diagnostic Test - Cyst Fluid

Cyst fluid will be obtained by already planned biopsy, either at Memorial Sloan Kettering Cancer Center or elsewhere

Additional Information

Official Study Title

Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma

Clinical Trial ID

NCT03334708

ParticipAid ID

7e5DZd